Pfizer Korea Signs Development Pact With State KRIBB For Liver and Gastric Cancer Drugs
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Two years after signing a memorandum of understanding on cooperation, Pfizer and Korea's state-run Korea Research Institute for Bioscience and Biotechnology signed a more formal agreement May 18 to start collaborative research work for joint development of drugs for liver and gastric cancer
You may also be interested in...
Korea's Samsung And Pfizer In Genome Research Partnership To Fight Liver Cancer
SEOUL - A month after an announcement about entering the biosimilars sector, South Korea's leading conglomerate, Samsung Group, is gearing up to get a stronger foothold in the pharmaceutical industry through establishing connections with established players
Korea's Samsung And Pfizer In Genome Research Partnership To Fight Liver Cancer
SEOUL - A month after an announcement about entering the biosimilars sector, South Korea's leading conglomerate, Samsung Group, is gearing up to get a stronger foothold in the pharmaceutical industry through establishing connections with established players
Pfizer Will Seek Out More R&D Opportunities in Korea
SEOUL - Pfizer Korea will seek more opportunities for R&D partnerships in Korea as it tries to develop treatments for Asia-prevalent liver and stomach cancers